Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23N3O2 |
| Molecular Weight | 349.427 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCN1c2ccccc2/C(=N/N=C(c3ccccc3)O)/C1=O
InChI
InChIKey=ZGQHMZCITJHYOW-QOCHGBHMSA-N
InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14H,2-4,10,15H2,1H3,(H,23,25)/b22-19-
| Molecular Formula | C21H23N3O2 |
| Molecular Weight | 349.427 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P21554|||Q5UB37 Gene ID: 1268.0 Gene Symbol: CNR1 Target Organism: Homo sapiens (Human) |
162.0 nM [Ki] | ||
Target ID: P34972 Gene ID: 1269.0 Gene Symbol: CNR2 Target Organism: Homo sapiens (Human) |
43.0 nM [Ki] | ||
Target ID: P20272 Gene ID: 25248.0 Gene Symbol: Cnr1 Target Organism: Rattus norvegicus (Rat) |
1.13 µM [Ki] | ||
Target ID: Q9QZN9 Gene ID: 57302.0 Gene Symbol: Cnr2 Target Organism: Rattus norvegicus (Rat) |
16.0 nM [Ki] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. | 2008 Aug 28 |
|
| Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. | 2010 Jul |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 22:51:44 UTC 2021
by
admin
on
Fri Jun 25 22:51:44 UTC 2021
|
| Record UNII |
X83OI5CX2U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MDA-19
Created by
admin on Fri Jun 25 22:51:44 UTC 2021 , Edited by admin on Fri Jun 25 22:51:44 UTC 2021
|
PRIMARY | MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects. | ||
|
X83OI5CX2U
Created by
admin on Fri Jun 25 22:51:44 UTC 2021 , Edited by admin on Fri Jun 25 22:51:44 UTC 2021
|
PRIMARY | |||
|
135743701
Created by
admin on Fri Jun 25 22:51:44 UTC 2021 , Edited by admin on Fri Jun 25 22:51:44 UTC 2021
|
PRIMARY | |||
|
MDA-19
Created by
admin on Fri Jun 25 22:51:44 UTC 2021 , Edited by admin on Fri Jun 25 22:51:44 UTC 2021
|
PRIMARY | CB2 receptor agonist. Displays 4-fold higher affinity for the human CB2 receptor than the human CB1 receptor (Ki values are 43.3 and 162.4 nM respectively) shows 70-fold affinity for the rat CB2 receptor over the rat CB1 receptor (Ki values are 16.3 and 1130 nM respectively). Attenuates tactile allodynia in a rat model does not affect rat locomotor activity. | ||
|
1104302-26-2
Created by
admin on Fri Jun 25 22:51:44 UTC 2021 , Edited by admin on Fri Jun 25 22:51:44 UTC 2021
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
1048973-47-2
Created by
admin on Fri Jun 25 22:51:44 UTC 2021 , Edited by admin on Fri Jun 25 22:51:44 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
